Saint-Gobain has appointed a former investment director of performance materials at M Ventures, Sven Harmsen, as director of external ventures for its Nova subsidiary.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Based on Clemson University research, 3D cancer cell modelling spinout Kiyatec has increased its total financing to $14.9m with the help of clinical lab operator LabCorp and VC firm VentureSouth.

Hannover Medical School chip cytometry spinout Zelkraftwerk has been bought by Canopy Biosciences, providing an exit for tech transfer company Ascenion.

Tom Risch has been appointed permanent executive director and vice-provost for research and tech transfer for Arkansas State University’s branch of the Arkansas Biosciences Institute.

The Tencent-backed cosmetic procedure-booking and social media platform floated at the top of its range in a US offering that came after more than $229m of funding.

Pharmstandard, Lung Biotechnology and Posco celebrated exits as the organ transportation system developer went public in a $91m offering.

Exosome therapeutics developer Codiak BioSciences, exploiting technology developed by researchers at the universities of Gothenburg and Texas, is eyeing up to $86.3m in an IPO.

Alexandria Real Estate Equities-backed exosome therapeutics developer Codiak BioSciences is eyeing up to $86.3m in a forthcoming IPO.

The immuno-oncology therapy developer received funding from investors including Alexandria Real Estate Equities and strategic collaborator Celgene.